E! 115054 SPECTROFLOW II Getica
| Reference number | |
| Coordinator | Getica AB - Getica AB, Göteborg |
| Funding from Vinnova | SEK 3 011 107 |
| Project duration | March 2021 - February 2024 |
| Status | Completed |
| Venture | Eurostars |
Important results from the project
The main goal of the project was to create an innovative platform for measuring plasma markers in whole blood with improved precision. From a technical standpoint, the project has followed the plan well, and we have successfully developed functional prototypes for three different markers varying in concentration levels.
Expected long term effects
During the project period, we have developed an innovative platform for measuring plasma markers in whole blood with improved precision. The concept is based on a method for measuring and compensating for the individual´s plasma fraction, which is crucial for the accuracy of the results. Three prototype products have been developed and internally evaluated with good results. However, it was found during the project period that the path to the market is a more complex and costly process than previously estimated, and the project has been paused as of December 31, 2023.
Approach and implementation
The project has been carried out in close collaboration with our project partner, Gentian AS. Throughout the project, we have held regular meetings and maintained an effective collaboration to develop functional prototypes. Getica has been primarily responsible for method development, reagent and test development, while our partner has handled the instrument development, IP, prototype validation, and project management. The well-functioning cooperation between the parties has been crucial in achieving the project´s objectives.